A pharma giant put millions into a biosciences startup developing an oral drug for obesity and metabolic disorders, adding to financing that venture capital firms invested in earlier.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
What would you ask Alexander the Great, Eleven from “Stranger Things” or Sherlock Holmes? The question forms the central conceit of character-based artificial intelligence chatbots, which have proliferated across the internet in the most recent […]
BOSTON – Dyno Therapeutics hosted an ambitious event in Boston this week, the Genome Agency Technology Conference (GATC)*, striving to bring together a broad coalition of researchers and executives in cell and gene therapy, gene […]
Jennifer Richer, PhD, takes the helm today as the new dean of the Graduate School. A member of the University of Colorado community for nearly 30 years, Richer has been a longtime member of the […]
Copyright © 2026 Biotech Networks
